At an extraordinary general meeting on
The decision at the extraordinary general meeting means that the merger is expected to be completed during the fourth quarter of 2023, in accordance with the communicated schedule.
"The merger with
"By merging two Swedish players, we are laying the foundation for a leading Swedish femtech company with strengthened opportunities to grow organically as well as through acquisitions. The Boards of Directors of Peptonic and
The merger enables faster growth in the important US market
Both Peptonic and
"The self-test VagiVital VS is Peptonic's bestselling product today, with the US being the single largest market. Being able to offer a patented self-care treatment to our existing test for bacterial vaginosis means a very strong offering that enables faster growth in existing channels," said
Positive profit contribution in 2024
The merger creates organizational synergies and broadens competence, which strengthens the ability to realize the sales potential in the existing offer, as well as continued development of the companies' technology platforms and broadening of the product portfolio. Overall, the New Peptonic gets reduced overhead costs to run the business, and a more cost-effective organization compared to the companies individually. It is estimated that
"We see good opportunities to realize synergies through the merger and thereby build a stronger player with better conditions to increase the growth rate and expand into new markets. With the New Peptonic, we intend to create a leading femtech company and we look forward to doing this together," said
Telefon: + 46 722 49 90 43
E-post: erik.sundquist@peptonicmedical.se
About
Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The "Medical Consumer" business area is based on clinically proven intimate self-care and is the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on menstruation, sex and fertility and is sold under the Lunette brand. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in
About
For more information visit www.pharmiva.com
https://news.cision.com/peptonic-medical-ab/r/the-merger-between-peptonic-and-pharmiva-creates-a-leading-global-femtech-company,c3820634
https://mb.cision.com/Main/11203/3820634/2238042.pdf
(c) 2023 Cision. All rights reserved., source